| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-26 136.50 0.48% | | | 1554.44万 | 1.84% | -172.46万 | -0.20% | -1381.98万 | -1.63% | | 2025-08-25 | 135.85 | 0.35% | - -1.06亿 | -10.51% | 2847.40万 | 2.83% | 7738.71万 | 7.68% | | 2025-08-22 135.38 1.18% | | | -2035.38万 | -2.18% | -5768.37万 | -6.17% | 7803.75万 | 8.35% | | 2025-08-21 133.80 | | 2.90% | -6385.25万 | -5.55% | -1328.60万 | -1.16% | 7713.85万 | 6.71% | | 2025-08-20 130.03 | | 0. ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight decline, with a closing price of 130.7 yuan on August 8, 2025, down by 1.1% [1] Group 1: Stock Performance and Trading Data - On August 8, 2025, the stock experienced a trading volume of 32,200 hands and a total transaction value of 424 million yuan [1] - The net inflow of main funds was 12.49 million yuan, accounting for 2.95% of the total transaction value, while retail investors saw a net outflow of 4.94 million yuan, representing 1.16% [1] - Over the past five days, the stock has fluctuated, with a peak closing price of 132.16 yuan on August 7, 2025, and a net inflow of main funds reaching 25.87 million yuan on that day [1] Group 2: Financial Metrics and Industry Comparison - United Imaging Healthcare's total market capitalization is 107.72 billion yuan, significantly higher than the industry average of 11.73 billion yuan, ranking 2nd in the industry [2] - The company reported a net profit of 370 million yuan for Q1 2025, reflecting a year-on-year increase of 1.87%, while its main revenue reached 2.478 billion yuan, up by 5.42% [2] - The company's gross profit margin stands at 49.94%, slightly below the industry average of 51.35%, while its net profit margin is 14.75%, above the industry average of 10.85% [2] Group 3: Analyst Ratings and Market Sentiment - In the last 90 days, 18 institutions have rated the stock, with 11 giving a "buy" rating and 7 an "accumulate" rating, indicating positive market sentiment [3] - The average target price set by institutions over the past 90 days is 149.48 yuan, suggesting potential upside from the current trading price [3]

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a price increase of 3.34% as of June 3, 2025, closing at 142.02 yuan, with significant net inflows from retail investors despite outflows from institutional and speculative funds [1][2]. Financial Performance - For Q1 2025, United Imaging Healthcare reported a main revenue of 2.478 billion yuan, a year-on-year increase of 5.42% [5]. - The net profit attributable to shareholders was 370 million yuan, up 1.87% year-on-year, while the net profit excluding non-recurring items was 379 million yuan, reflecting a 26.09% increase [5]. - The company has a debt ratio of 29.69% and reported investment income of 14.53 million yuan, with financial expenses of -16.94 million yuan [5]. Market Activity - On June 3, 2025, the stock experienced a trading volume of 67,700 hands and a total transaction amount of 962 million yuan [1]. - The net outflow of main funds was 56.20 million yuan, accounting for 5.84% of the total transaction amount, while retail investors saw a net inflow of 118 million yuan, representing 12.28% of the total [1][2]. Financing and Margin Trading - As of June 3, 2025, the financing balance was 370 million yuan, with a net repayment of 2.44 million yuan for the day [3]. - The margin trading balance stood at 376 million yuan, with a short selling volume of 876 shares and a remaining short selling balance of 632,320 yuan [3]. Industry Comparison - United Imaging Healthcare's total market capitalization is 117.05 billion yuan, significantly higher than the industry average of 10.84 billion yuan, ranking 2nd among 122 companies in the medical device sector [5]. - The company's net asset value is 20.28 billion yuan, also ranking 3rd in the industry [5]. - The price-to-earnings ratio (P/E) is 79.07, which is higher than the industry average of 55.75, ranking 77th [5]. Analyst Ratings - In the last 90 days, 26 institutions have rated the stock, with 17 buy ratings and 9 hold ratings, and the average target price set at 155.65 yuan [6].